Effect of pterostilbene on lipids and lipid profiles in streptozotocin-nicotinamide induced type 2 diabetes mellitus

Abstract

Hyperlipidaemia is one of the major risk factors of cardiovascular complication in diabetes. A study was undertaken to evaluate the antihyperlipidaemic activity of pterostilbene. Oral administration of pterostilbene (40mg/kg bodyweight) to streptozotocin-nicotinamide induced diabetic rats for 6 weeks significantly reduced the elevated serum very low density lipoprotein (VLDL) and low density lipoprotein (LDL)-cholesterol levels and significantly increased the serum high-density lipoprotein (HDL)-cholesterol level. In addition, pterostilbene also significantly lowered the levels of triglycerides, phospholipids, free fatty acids and total cholesterol in the serum, liver and kidney of diabetic rats.